Results 201 to 210 of about 5,659,298 (338)

The European Society for Medical Oncology (ESMO) Precision Medicine Glossary.

Annals of Oncology, 2018
Lucy R. Yates, J. Seoane, C. Tourneau, C. Tourneau, L. Siu, Richard Marais, S. Michiels, Jeannette Soria, Peter J. Campbell, Nicola Normanno, A. Scarpa, J. Reis-Filho, Jordi Rodon, C. Swanton, Fabrice André   +14 more
semanticscholar   +1 more source

Cytoplasmic p21 promotes stemness of colon cancer cells via activation of the NFκB pathway

Molecular Oncology, EarlyView.
Cytoplasmic p21 promotes colorectal cancer stem cell (CSC) features by destabilizing the NFκB–IκB complex, activating NFκB signaling, and upregulating BCL‐xL and COX2. In contrast to nuclear p21, cytoplasmic p21 enhances spheroid formation and stemness transcription factor CD133.
Arnatchai Maiuthed, Kerstin Huebner, Katharina Erlenbach‐Wuensch, Chuanpit Hampel, Daniela Thalheim, Adriana Vial‐Roehe, Bodee Nutho, Susanne Merkel, Arndt Hartmann, Pithi Chanvorachote, Regine Schneider‐Stock   +10 more
wiley   +1 more source

Patients' education through scientifically-popular material [PDF]

Archive of Oncology, 2002
Jovanović Biljana, Brzaković Predrag, Jovićević-Bekić Ana, Mirković Verica, Živković Rada, Delić Jela   +5 more
doaj   +1 more source

Progressive role of artificial intelligence in treatment decision-making in the field of medical oncology. [PDF]

Front Med (Lausanne)
Bongurala AR, Save D, Virmani A.
europepmc   +1 more source

Medical imaging and nuclear medicine: a Lancet Oncology Commission.

The Lancet Oncology, 2021
H. Hricak, M. Abdel-Wahab, R. Atun, M. M. Lette, D. Paez, J. Brink, Lluís Donoso-Bach, G. Frija, Monika Hierath, O. Holmberg, P. Khong, Jason S. Lewis, G. McGinty, W. Oyen, L. Shulman, Zachary J. Ward, A. Scott   +16 more
semanticscholar   +1 more source

Class IIa HDACs forced degradation allows resensitization of oxaliplatin‐resistant FBXW7‐mutated colorectal cancer

Molecular Oncology, EarlyView.
HDAC4 is degraded by the E3 ligase FBXW7. In colorectal cancer, FBXW7 mutations prevent HDAC4 degradation, leading to oxaliplatin resistance. Forced degradation of HDAC4 using a PROTAC compound restores drug sensitivity by resetting the super‐enhancer landscape, reprogramming the epigenetic state of FBXW7‐mutated cells to resemble oxaliplatin ...
Vanessa Tolotto, Nicolò Gualandi, Ylenia Cortolezzis, Raffaella Picco, Monica Colitti, Francesca D'Este, Mariachiara Gani, Wayne W. Hancock, Giovanni Terrosu, Cristina Degrassi, Francesca Agostini, Claudio Brancolini, Luigi E. Xodo, Eros Di Giorgio   +13 more
wiley   +1 more source

Correction: Biomarkers in gastroesophageal cancer 2025: an updated consensus statement by the Spanish Society of Medical Oncology (SEOM) and the Spanish Society of Pathology (SEAP). [PDF]

Clin Transl Oncol
Alsina Maqueda M, Teijo Quintáns A, Cuatrecasas M, Fernández Aceñero MJ, Fernández Montes A, Gómez Martín C, Jiménez Fonseca P, Martínez Ciarpaglini C, Rivera Herrero F, Iglesias Coma M.   +9 more
europepmc   +1 more source

Medical Oncology [PDF]

, 2018
林 龍二, 梶浦 新也, 菓子井 達彦   +2 more
core   +2 more sources

In vitro models of cancer‐associated fibroblast heterogeneity uncover subtype‐specific effects of CRISPR perturbations

Molecular Oncology, EarlyView.
Development of therapies targeting cancer‐associated fibroblasts (CAFs) necessitates preclinical model systems that faithfully represent CAF–tumor biology. We established an in vitro coculture system of patient‐derived pancreatic CAFs and tumor cell lines and demonstrated its recapitulation of primary CAF–tumor biology with single‐cell transcriptomics ...
Elysia Saputra, Shamsudheen Karuthedath Vellarikkal, Lixia Li, Hong Sun, Khoa Nguyen, Amber Montano, Suchitra Natarajan, Federica Piccioni, Alex Michael Tamburino, Xin Yu, Aleksandra Katarzyna Olow   +10 more
wiley   +1 more source

Sexual health in cancer care: a narrative review and position statement from the Italian Association of Medical Oncology (AIOM). [PDF]

ESMO Open
Rossi A, Leone AG, Lambertini M, Sperti E, Cassani C, Vetromile A, Barni S, De Giorgi A, Preti EP, Secondino S, Silvestris N, Berardi R, Brunello A, Curigliano G, La Verde N, Latiano TP, Pietrantonio F, Tiseo M, Di Maio M, Perrone F, Cinieri S, Fabi A, Associazione Italiana Oncologia Medica (AIOM).   +22 more
europepmc   +1 more source